CTHRC1 inhibitors could potentially be used as adjuvant treatment alongside BRAF(V600E)-targeted drugs in BRAF(V600E) mutant colon cancer, thyroid cancer, and melanoma. The gene discussed is BRAF; the disease is thyroid gland carcinoma.